Biomarkers in lung oncology

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 6, 2010, Pages 508-514

  Rosell, Rafael ^a,b   Vergnenegre, Alain ^c   Liu, Baorui ^d   Cobo, Manuel ^e   Massuti, Bartomeu ^f   Wei, Jia ^d   Molina, Miguel Angel ^b   Costa, Carlota ^b   Queralt, Cristina ^a   Taron, Miquel ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d NANJING UNIVERSITY   (China)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

BRCA1; Customized chemotherapy; EGFR mutations; Non small cell lung cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MESSENGER RNA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; DISEASE FREE SURVIVAL; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA DAMAGE; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 78649332948     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.05.003     Document Type: Article

References (82)

1. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
2. Burdett S., Johnson D., Stewart L., Tierney J., Le Pechoux C., et al. Supportive care and chemotherapy (CT) versus supportive care alone in advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised controlled trials (RCTs). J Thorac Oncol 2007, S337. Seoul, Korea, [abstr B332-303].
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
4. Rosell R., Mendez P., Isla D., Taron M. Platinum resistance related to a functional NER pathway. J Thorac Oncol 2007, 2:1063-1066.
5. Rajewsky M., Müller R. DNA repair and the cell cycle as targets in cancer therapy. The cancer handbook 2002, 1507-1519. Nature Publishing Group, London, UK. M. Alison (Ed.).
6. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
7. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
8. Rosell R., Skrzypski M., Jassem E., Taron M., Bartolucci R., et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007, 2:e1129.
9. Wei J., Zou Z., Qian X., Ding Y., Xie L., et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008, 98:1398-1402.
10. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756.
11. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
12. Johnson C.D., Esquela-Kerscher A., Stefani G., Byrom M., Kelnar K., et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007, 67:7713-7722.
13. Rosell R, Manegold C, Moran T, Garrido P, Blanco R, et al. Can we customize chemotherapy? individualizing cytotoxic regimens in advanced non-small-cell lung cancer. Clin Lung Cancer;9(Suppl. 2), in press.
14. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994, 94:703-708.
15. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998, 16:309-316.
16. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
17. Rosell R., Scagliotti G., Danenberg K.D., Lord R.V., Bepler G., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003, 22:3548-3553.
18. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10:1318-1325.
19. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17:1818-1825.
20. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007, 2:902-906.
21. Rosell R., Felip E., Taron M., Majo J., Mendez P., et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004, 10:4215-4219.
22. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443-2449.
23. Quinn J.E., Kennedy R.D., Mullan P.B., Gilmore P.M., Carty M., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63:6221-6228.
24. Quinn J.E., James C.R., Stewart G.E., Mulligan J.M., White P., et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007, 13:7413-7420.
25. Jensen R.A., Page D.L., Holt J.T. Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. Proc Natl Acad Sci U S A 1994, 91:9257-9261.
26. Xu X., Page J.L., Surtees J.A., Liu H., Lagedrost S., et al. Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res 2008, 68:2652-2660.
27. Souglakos J., Boukovinas I., Taron M., Mendez P., Mavroudis D., et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 2008.
28. Su T.T. Cellular responses to DNA damage: one signal, multiple choices. Annu Rev Genet 2006, 40:187-208.
29. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192.
30. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
31. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol Cell 2007, 28:739-745.
32. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
33. Wang B., Matsuoka S., Ballif B.A., Zhang D., Smogorzewska A., et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007, 316:1194-1198.
34. O'Connell B.C., Harper J.W. Ubiquitin proteasome system (UPS): what can chromatin do for you?. Curr Opin Cell Biol 2007, 19:206-214.
35. Guerrero-Santoro J., Kapetanaki M.G., Hsieh C.L., Gorbachinsky I., Levine A.S., et al. The cullin 4B-based UV-damaged DNA-binding protein ligase binds to UV-damaged chromatin and ubiquitinates histone H2A. Cancer Res 2008, 68:5014-5022.
36. Sugasawa K. Xeroderma pigmentosum genes: functions inside and outside DNA repair. Carcinogenesis 2008, 29:455-465.
37. Adler A.S., Lin M., Horlings H., Nuyten D.S., van de Vijver M.J., et al. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 2006, 38:421-430.
38. Lue H., Thiele M., Franz J., Dahl E., Speckgens S., et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007, 26:5046-5059.
39. Adler A.S., Littlepage L.E., Lin M., Kawahara T.L., Wong D.J., et al. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res 2008, 68:506-515.
40. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008, 8:83-93.
41. Akhoondi S., Sun D., von der Lehr N., Apostolidou S., Klotz K., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67:9006-9012.
42. Deeb K.K., Michalowska A.M., Yoon C.Y., Krummey S.M., Hoenerhoff M.J., et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007, 67:8065-8080.
43. Menssen A., Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A 2002, 99:6274-6279.
44. Sobhian B., Shao G., Lilli D.R., Culhane A.C., Moreau L.A., et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007, 316:1198-1202.
45. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868.
46. Wang B., Elledge S.J. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci U S A 2007, 104:20759-20763.
47. Chen X., Arciero C.A., Wang C., Broccoli D., Godwin A.K. BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. Cancer Res 2006, 66:5039-5046.
48. Stewart G.S., Wang B., Bignell C.R., Taylor A.M., Elledge S.J. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 2003, 421:961-966.
49. Kim H., Chen J., Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007, 316:1202-1205.
50. Yan J., Kim Y.S., Yang X.P., Li L.P., Liao G., et al. The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res 2007, 67:6647-6656.
51. Morris J.R., Boutell C., Keppler M., Densham R., Weekes D., et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009, 462:886-890.
52. Galanty Y., Belotserkovskaya R., Coates J., Polo S., Miller K.M., et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009, 462:935-939.
53. Rosell R., Perez-Roca L., Sanchez J.J., Cobo M., Moran T., et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 2009, 4:e5133.
54. Chang H.Y., Sneddon J.B., Alizadeh A.A., Sood R., West R.B., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7.
55. Gazdar A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009.
56. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
57. Inoue A., Kobayashi K., Usui K., Maemondo M., Okinaga S., et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009, 27:1394-1400.
58. Linardou H., Dahabreh I.J., Bafaloukos D., Kosmidis P., Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009, 6:352-366.
59. Bai H., Mao L., Wang H.S., Zhao J., Yang L., et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27:2653-2659.
60. Tam I.Y., Leung E.L., Tin V.P., Chua D.T., Sihoe A.D., et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 2009, 8:2142-2151.
61. Chitale D., Gong Y., Taylor B.S., Broderick S., Brennan C., et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009, 28:2773-2783.
62. Schmid K., Oehl N., Wrba F., Pirker R., Pirker C., et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009, 15:4554-4560.
63. Costa D.B., Nguyen K.S., Cho B.C., Sequist L.V., Jackman D.M., et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008, 14:7060-7067.
64. Ichihara E., Ohashi K., Takigawa N., Osawa M., Ogino A., et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res 2009, 69:5091-5098.
65. Nguyen K.S., Kobayashi S., Costa D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10:281-289.
66. Zhou W., Ercan D., Chen L., Yun C.H., Li D., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
67. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
68. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006, 66:7854-7858.
69. Kuang Y., Rogers A., Yeap B.Y., Wang L., Makrigiorgos M., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15:2630-2636.
70. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
71. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
72. Pao W., Miller V., Zakowski M., Doherty J., Politi K., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
73. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11:5878-5885.
74. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
75. Smouse J.H., Cibas E.S., Janne P.A., Joshi V.A., Zou K.H., et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009, 117:67-72.
76. Molina-Vila M.A., Bertran-Alamillo J., Reguart N., Taron M., Castella E., et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008, 3:1224-1235.
77. Morita S., Okamoto I., Kobayashi K., Yamazaki K., Asahina H., et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009, 15:4493-4498.
78. Miyazawa H., Tanaka T., Nagai Y., Matsuoka M., Sutani A., et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci 2008, 99:595-600.
79. Yu J., Kane S., Wu J., Benedettini E., Li D., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15:3023-3028.
80. Motoi N., Szoke J., Riely G.J., Seshan V.E., Kris M.G., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32:810-827.
81. De Oliveira Duarte Achcar R., Nikiforova M.N., Yousem S.A. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 2009, 131:694-700.
82. Gazdar A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009, 361:1018-1020.